Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on LY03020 in healthy subjects
NCT07292233Phase 1Active, not recruiting
- Sponsor
- Luye Pharma Group
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lpm787000048 maleate in schizophrenia and Alzheimer's disease (AD) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Maximum observed concentration at Day 12, Area under the concentration-time curve from time zero extrapolated to infinity at Day 12 and 1 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
lpm787000048 maleate
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07292233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292233.